NasdaqGM:ATRC

Stock Analysis Report

Executive Summary

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally.

Snowflake

Fundamentals

Reasonable growth potential with adequate balance sheet.

Risks

  • AtriCure has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has AtriCure's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.9%

NasdaqGM:ATRC

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-24.3%

NasdaqGM:ATRC

9.7%

US Medical Equipment

1.9%

US Market

ATRC underperformed the Medical Equipment industry which returned 9.6% over the past year.

ATRC underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

ATRCIndustryMarket
7 Day8.9%1.5%0.8%
30 Day-4.8%0.7%3.4%
90 Day-14.9%2.4%2.1%
1 Year-24.3%-24.3%10.6%9.7%4.2%1.9%
3 Year62.9%62.9%70.2%65.0%46.7%37.2%
5 Year76.2%76.2%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is AtriCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AtriCure undervalued based on future cash flows and its price relative to the stock market?

4.17x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

AtriCure's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

AtriCure's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

AtriCure is loss making, we can't compare its value to the US Medical Equipment industry average.

AtriCure is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for AtriCure, we can't assess if its growth is good value.


Price Based on Value of Assets

AtriCure is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is AtriCure expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

33.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

AtriCure's revenue is expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).

AtriCure's earnings are expected to grow significantly at over 20% yearly.

AtriCure's revenue growth is expected to exceed the United States of America market average.

AtriCure's earnings growth is expected to exceed the United States of America market average.

AtriCure's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if AtriCure will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has AtriCure performed over the past 5 years?

-3.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

AtriCure does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare AtriCure's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare AtriCure's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if AtriCure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if AtriCure has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if AtriCure improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is AtriCure's financial position?


Financial Position Analysis

AtriCure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

AtriCure's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

AtriCure's level of debt (16.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 16.3% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

AtriCure has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if AtriCure has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is AtriCure's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate AtriCure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate AtriCure's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as AtriCure has not reported any payouts.

Unable to verify if AtriCure's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as AtriCure has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of AtriCure's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Mike Carrel (48yo)

6.8yrs

Tenure

US$3,807,997

Compensation

Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President of AtriCure, Inc. at Endoscopic Technologies, Inc. since November 2012. Mr. Carrel has been Director since Feb ...


CEO Compensation Analysis

Mike's remuneration is higher than average for companies of similar size in United States of America.

Mike's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.1yrs

Average Tenure

48yo

Average Age

The tenure for the AtriCure management team is about average.


Board Age and Tenure

2.8yrs

Average Tenure

64yo

Average Age

The average tenure for the AtriCure board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by AtriCure individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$12,43016 Sep 19
Regina Groves
EntityIndividual
Role
Member of the Board of Directors
Director
Shares500
Max PriceUS$24.86
SellUS$6,733,90009 Oct 18
Hudson Executive Capital LP
EntityCompany
Shares205,000
Max PriceUS$32.86

Ownership Breakdown


Management Team

  • Mike Carrel (48yo)

    CEO & President

    • Tenure: 6.8yrs
    • Compensation: US$3.81m
  • Salvatore Privitera (52yo)

    Chief Technology Officer

    • Tenure: 2.2yrs
    • Compensation: US$1.12m
  • Theodore Polin

    Corporate Secretary

    • Tenure: 0yrs
  • Andy Wade (44yo)

    Senior VP & CFO

    • Tenure: 6.7yrs
    • Compensation: US$1.55m
  • Doug Seith (53yo)

    Chief Operating Officer

    • Tenure: 4.7yrs
    • Compensation: US$1.79m
  • Tonya Austin

    Senior Vice President of Human Resources

    • Tenure: 0yrs
  • Karl Dahlquist

    Senior VP

    • Tenure: 0yrs
  • Justin Noznesky (41yo)

    Senior Vice President of Marketing & Business Development

    • Tenure: 3.5yrs
    • Compensation: US$1.22m
  • Valerie Storch-Willhaus

    Senior Director of Corporate Marketing & Communications

    • Tenure: 0yrs
  • Vini Doraiswamy

    Senior Vice President of Clinical

    • Tenure: 2.5yrs

Board Members

  • Sven Wehrwein (68yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$199.57k
  • B. Johnson (67yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$319.45k
  • Mark Collar (66yo)

    Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$192.49k
  • Mark Lanning (64yo)

    Director

    • Tenure: 13.6yrs
    • Compensation: US$199.99k
  • Scott Drake (51yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: US$216.43k
  • Bob White (57yo)

    Independent Director

    • Tenure: 6.5yrs
    • Compensation: US$191.08k
  • Reggie Groves (61yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$316.95k

Company Information

AtriCure, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AtriCure, Inc.
  • Ticker: ATRC
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.027b
  • Shares outstanding: 39.49m
  • Website: https://www.atricure.com

Number of Employees


Location

  • AtriCure, Inc.
  • 7555 Innovation Way
  • Mason
  • Ohio
  • 45040
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2005
A5IDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2005

Biography

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Syn ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:54
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.